CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...

Viyaara Realty, a premier Mumbai-based real estate developer, dedicated to creating exceptional living spaces is set to ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk's experimental drug, CagriSema, demonstrated a 15.7% weight reduction in obese individuals with type 2 diabetes over 68 weeks. Key findings from the phase III REDEFINE 2 trial highlight ...

Whether for home, work, or daily routines, these inventions redefine modern problem-solving with fresh ideas and cutting-edge technology. Russia Responds to Ukraine-US Ceasefire Agreement Best ...

MELVILLE, N.Y., Feb. 5, 2025 /PRNewswire/ -- Today, Nikon Inc. announced the highly anticipated release of the NIKKOR Z 35mm f/1.2 S, a medium wide-angle prime lens with an impressively fast f/1.2 ...

A piece of state legislation is seeking to amend the Arkansas Freedom of Information Act to set a long-sought definition ...

today announced the closing of its $2.6 million seed funding round. The funding was led by a group of influential angel investors, cybersecurity experts, and technology experts who recognize the ...

Wonder Land: When progressives single out threats to "our democracy," what they mean is their democracy. Images: Everett Collection/AFP/Getty Images Composite: Mark Kelly Insightful videos ...